| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Part 8: Regional Perspectives in PD |
Shafa CAPD Research Center and Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Correspondence to: I. Najafi, Department of Internal Medicine, Dr. Shariati Hospital, Tehran University of Medical Sciences, North Kargar Avenue, Tehran 14114 Iran. najafi63800{at}yahoo.com
The countries of the Middle East have a cumulative population of 261.1
million and a mean gross national income per capita of US$9500. The total
number of patients with end-stage renal disease (ESRD) in the Middle East is
almost 100 000, the mean prevalence being 430 per million population (pmp).
The first implementation of intermittent peritoneal dialysis (PD) in the
Middle East occurred in Turkey in 1968; continuous ambulatory PD started in
Saudi Arabia, Turkey, and Kuwait in the 1980s; and automated PD, in Turkey in
1998. The total active PD patients in the region number approximately 8170.
With 5750 patients, Turkey ranks first, followed by Iran and Saudi Arabia with
1150 and 771 patients respectively. Penetration of PD with respect to the ESRD
population is 7.5%, and with respect to dialysis overall is 10.2%. The
dialysis rate in the region, 312 pmp, is almost half the European number of
581 pmp, with a PD prevalence of 32 pmp (range: 0 – 81 pmp). The number
of active PD patients has risen dramatically in the main countries since the
end of the 1990s: Turkey, to 5750 from 1030; Saudi Arabia, to 771 from 132;
and Iran to 1150 from 0.
KEY WORDS: Middle East; Iran; renal replacement therapy; dialysis prevalence; CAPD.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
